login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Preliminary results of CT angiography method for assessing haemodynamic significance of coronary lesions released


Wednesday, 11 Jul 2012 12:05
COR Analyzer
COR Analyzer


On 10 July, Rcadia Medical Imaging announced results of an initial study intended to demonstrate the feasibility of a proprietary technique that uses coronary CT angiography studies (cCTA) as a non-invasive alternative to assess the haemodynamic significance of coronary lesions.


“Determining the effect of an intermediate lesion on coronary blood flow is critical to making a treatment decision,” said Shai Levanon, president and CEO, Rcadia. “Currently, the standard technique for evaluating the haemodynamic significance of coronary lesions is by measuring fractional flow reserve (FFR) through invasive coronary catheterisation. Our initial study shows a good correlation to FFR, highlighting the potential of our technology to enhance the diagnostic utility of cCTA and reduce the number of invasive, costly diagnostic cardiac catheterisation produces.”

Levanon noted that Rcadia’s approach builds on its FDA cleared COR Analyzer System, which performs fully automatic detection of coronary stenosis from cCTA studies. “A capability for assessing haemodynamic significance has potential to provide a powerful complement to the COR Analyzer’s ability to identify significant stenosis in suspected patients with coronary artery disease.”


To assess the diagnostic performance of the method, Rcadia conducted a retrospective study based on 44 patients who underwent both cCTA and diagnostic coronary catheterisation with FFR measurements. Assessments using Rcadia’s proprietary technique were performed for 49 of 51 lesions with FFR measurements present in those studies. Two lesions were not evaluated due to poor image quality.


The Rcadia method correctly identified all 11 haemodynamically significant lesions (FFR <=0.8) and 33 of 38 haemodynamically insignificant lesions (FFR>0.8), yielding the sensitivity of 100% and specificity of 87%.




Add New Comment

Related Items


Most popular


Friday, 22 Aug 2014
Royal Philips has announced that it has received 510(k) clearance from the US Food and Drug Administration to market its precision planning application for transcatheter aortic-valve implantation (TAV... FDA 510(k) clearance for TAVI precision treatment planning application

Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published
Wednesday, 27 Aug 2014
A new European joint consensus document on the use of antithrombotic drugs in patients with atrial fibrillation presenting with an acute coronary syndrome and undergoing percutaneous coronary ... Joint consensus on antithrombotic use in AF patients with acute coronary syndrome published

No severe paravalvular leak with Acurate Neo TF
Monday, 29 Sep 2014
Data presented at PCR London Valves (28–30 September, London, UK) indicate that the Acurate Neo transfemoral TAVI system, which recently received the CE mark, is not associated with any incidences of ... No severe paravalvular leak with Acurate Neo TF

Features


The promise of chemical renal denervation
Friday, 05 Sep 2014
Tim A Fischell writes that chemical renal denervation using ethanol may have numerous advantages over energy-based “burning” technologies. The promise of chemical renal denervation

Drug-coated balloons for the management of coronary artery disease
Thursday, 04 Sep 2014
Robert Byrne writes that although drug-coated balloon therapy has been a significant innovation with relevance for everyday practice, convincing data in the coronary arena exists thus far only for ... Drug-coated balloons for the management of coronary artery disease

Profiles


Azeem Latib
Wednesday, 24 Sep 2014
Azeem Latib (senior interventional cardiologist, San Raffaele Hospital and EMO-GVM Centro Cuore C... Azeem Latib

David J Cohen
Wednesday, 04 Jun 2014
David J Cohen, director, Cardiovascular Research, Saint Luke’s Mid America Heart Institute, Kansas C... David J Cohen

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions